Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is advancing its product pipeline, notably its next-generation COVID-19 vaccine, GEO-CM04S1, which has demonstrated positive Phase 2 performance in immunocompromised populations and potential against hematologic cancers. The company has received favorable regulatory feedback for its Mpox/Smallpox vaccine, GEO-MVA, and continues to explore innovative delivery methods, enhancing its strategic position in the market. Despite a currently distressed valuation, there is potential for upside as management actively engages in investor outreach and monitors sector dynamics that could present further strategic opportunities.

Bears say

Geovax Labs Inc faces heightened execution risk due to low liquidity, a depressed share price, and a challenging funding environment, which has resulted in limited cash reserves of only $5 million as of Q3. The company's high cash burn rate in conjunction with ongoing research and development investments raises the likelihood of needing additional financing, exacerbating concerns about potential dilution and funding uncertainty. Furthermore, the broader biotechnology sector is experiencing significant funding pressures, with nearly 40% of public biotech firms projected to deplete their cash within 12 months, constraining investor appetite for firms perceived as higher risk.

Geovax Labs (GOVX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.